TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04236882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive educational material on healthy homes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive web-based sleep intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive web-based sleep intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive web-based health coaching sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive web-based health coaching sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Receive web-based counseling sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02864251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study: NCT04236882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02864251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days
Study: NCT03296254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting Mindfulness Exercises.
Description: 5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting Mindfulness Exercises.
Description: 5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Mindfulness Exercises
Description: 5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Mindfulness Exercises
Description: 5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
Study: NCT01165255

Intervention type: DRUG
Intervention: 3. Exposure to other antidepressants during the first trimester comparison cohort
Description: Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy.

Intervention type: DRUG
Intervention: 2. Exposure to bupropion outside the first trimester comparison cohort
Description: Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester.

Intervention type: DRUG
Intervention: 1. Exposure to bupropion during the first trimester
Description: Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy.
Study: NCT02404376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Intravenous administration of Exenatide
Study: NCT03930550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation by endoscopy with flexible bronchoscope
Description: A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation by endoscopy with flexible bronchoscope
Description: A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
Study: NCT02418988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE plus rAd-p53 artery injection
Description: Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
Study: NCT04011670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg caffeine tablet
Description: * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-active tablet
Description: * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition
Study: NCT02404376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: Remote ischemic conditioning with a cuff in the arm
Study: NCT00609999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib and Dasatinib
Description: You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib and Dasatinib
Description: You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
Study: NCT04036110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg
Description: 500 mg tablet taken orally with one meal daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg
Description: 1000 mg tablet taken orally with one meal daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet taken orally with one meal daily
Study: NCT00022334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP
Description: Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
Study: NCT00385008

Intervention type: DRUG
Group type: OTHER
Intervention: Combination Product (sumatriptan succinate / naproxen sodium)
Description: sumatriptan/naproxen sodium

Intervention type: DRUG
Group type: OTHER
Intervention: RELPAX(eletriptan) 40mg Tablet
Description: eletriptan tablets
Study: NCT00616070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Description: Difluprednate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT01285297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Injection of up to 18 mL BMAC
Study: NCT01936506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training A

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training B
Study: NCT02304497

Intervention type: OTHER
Intervention: Platelet Rich Fibrin
Description: Procedure: Platelet Rich Fibrin obtained

Intervention type: OTHER
Intervention: Platelet Rich Fibrin
Description: Procedure: Platelet Rich Fibrin obtained

Intervention type: OTHER
Intervention: Platelet Rich Fibrin
Description: Procedure: Platelet Rich Fibrin obtained

Intervention type: OTHER
Intervention: Platelet Rich Fibrin
Description: Procedure: Platelet Rich Fibrin obtained
Study: NCT02310256

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Five plus exercise training
Description: calf raise exercise
Study: NCT01799044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Tumor ablation with irreversible electroporation with the NanoKnife
Study: NCT02732171

Intervention type: OTHER
Group type: OTHER
Intervention: Research Blood Collection
Description: Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
Study: NCT00934687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clostridium botulinum toxin type A neurotoxin complex
Description: A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: 0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
Study: NCT02404376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: Remote ischemic conditioning with a cuff in the arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: Remote ischemic conditioning with a cuff in the arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: Remote ischemic conditioning with a cuff in the arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intrevenous administration of Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intrevenous administration of Placebo
Study: NCT02418988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
Study: NCT03024645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be A Mom
Description: The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
Study: NCT02255721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHIP (Sleep Health in Preschoolers)
Description: SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHIP Control Arm
Description: Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
Study: NCT03024645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usually (TAU)
Description: performed in primary care settings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usually (TAU)
Description: performed in primary care settings
Study: NCT01944579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackberries
Description: Participants will receive blackberries as part of a controlled diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackberries
Description: Participants will receive blackberries as part of a controlled diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will receive a control food (jello) as part of a controlled diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will receive a control food (jello) as part of a controlled diet.
Study: NCT00316888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT01693510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition Intervention
Description: Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
Study: NCT01867203

Intervention type: OTHER
Intervention: Genotyping
Description: DNA extraction from blood
Study: NCT01228578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin supplements B,C and E
Description: One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin supplements B,C and E
Description: One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
Study: NCT02487303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Intravenous
Description: IV 1 gram f3 doses over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Oral
Description: Oral 1 gram 3 doses over 24 hours
Study: NCT00316888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Given once daily 5 days a week for 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Given once daily 5 days a week for 5 weeks
Study: NCT00584571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Adaptation Training
Description: This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Therapy
Description: Escitalopram; 10 mg every day, orally.
Study: NCT01837667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100 for Injection
Description: Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
Study: NCT04059679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: EC aspirin 81 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: EC aspirin 81 mg qd
Study: NCT00614315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR™ Endovascular Stent Graft
Description: The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
Study: NCT00651326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Study: NCT03007992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
Study: NCT01106014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Selexipag 200 µg tablets
Study: NCT01669915

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study: NCT04263207

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01710956

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy
Description: Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy
Description: Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)